



US011382957B2

(12) United States Patent
Sauerberg et al.**(10) Patent No.: US 11,382,957 B2****(45) Date of Patent: *Jul. 12, 2022****(54) SOLID COMPOSITIONS COMPRISING A
GLP-1 AGONIST AND A SALT OF
N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC
ACID****(71) Applicant: Novo Nordisk A/S, Bagsvaerd (DK)****(72) Inventors: Per Sauerberg, Farum (DK); Simon
Bjerregaard, Hilleroed (DK);
Flemming Seier Nielsen, Frederikssund
(DK)****(73) Assignee: Novo Nordisk A/S, Bagsvaerd (DK)****(*) Notice:** Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.This patent is subject to a terminal dis-
claimer.**(21) Appl. No.: 17/180,370****(22) Filed: Feb. 19, 2021****(65) Prior Publication Data**

US 2021/0177944 A1 Jun. 17, 2021

Related U.S. Application Data**(63)** Continuation of application No. 16/118,381, filed on
Aug. 30, 2018, now Pat. No. 10,960,052, which is a
continuation of application No. 15/019,412, filed on
Feb. 9, 2016, now Pat. No. 10,086,047, which is a
continuation of application No. 13/994,262, filed as
application No. PCT/EP2011/073060 on Dec. 16,
2011, now Pat. No. 9,278,123.**(60)** Provisional application No. 61/425,087, filed on Dec.
20, 2010.**(30) Foreign Application Priority Data**

Dec. 16, 2010 (EP) 10195285

(51) Int. Cl.**A61P 3/04** (2006.01)
A61P 3/10 (2006.01)
A61K 9/20 (2006.01)
A61K 38/26 (2006.01)
A61K 9/00 (2006.01)
A61K 45/06 (2006.01)
A61K 47/18 (2017.01)
A61K 31/195 (2006.01)**(52) U.S. Cl.**CPC **A61K 38/26** (2013.01); **A61K 9/0053**
(2013.01); **A61K 9/2013** (2013.01); **A61K**
9/2077 (2013.01); **A61K 31/195** (2013.01);
A61K 45/06 (2013.01); **A61K 47/18** (2013.01)**(58) Field of Classification Search**CPC combination set(s) only.
See application file for complete search history.**(56) References Cited**

U.S. PATENT DOCUMENTS

5,545,618 A 8/1996 Buckley et al.
5,574,010 A 11/1996 McFadden
5,604,203 A 2/1997 Balasubramaniam
5,773,647 A 6/1998 Leone-Bay et al.
5,866,536 A 2/1999 Leone-Bay et al.
5,968,899 A 10/1999 Sekine et al.
6,046,167 A 4/2000 Balasubramaniam
6,071,510 A 6/2000 Leone-Bay et al.
6,268,343 B1 7/2001 Knudsen et al.
6,348,447 B1 2/2002 Hellstrom et al.
6,458,924 B2 10/2002 Knudsen et al.
7,049,283 B2 5/2006 Ault et al.
7,235,627 B2 6/2007 Knudson et al.
7,271,149 B2 9/2007 Glaesner et al.
7,417,028 B2 8/2008 Ewing et al.
8,022,035 B2 9/2011 Schwartz et al.
8,039,018 B2 10/2011 Majuru et al.
8,053,429 B2 11/2011 Cumming et al.
8,097,698 B2 1/2012 Knudsen et al.
8,536,122 B2 9/2013 Lau et al.
8,648,041 B2 2/2014 Garibay et al.
8,895,694 B2 11/2014 Spetzler et al.
8,901,073 B2 12/2014 Bloom
9,067,977 B2 6/2015 Spetzler et al.
9,085,637 B2 7/2015 Oestergaard et al.
9,186,392 B2 11/2015 Klein et al.
9,266,940 B2 2/2016 Wiczorek et al.
9,278,123 B2 3/2016 Sauerberg et al.
9,527,900 B2 12/2016 Linderroth et al.
9,993,430 B2 6/2018 Jensen et al.
10,086,047 B2 10/2018 Sauerberg et al.
10,246,497 B2 4/2019 Oestergaard et al.
10,278,923 B2 5/2019 Nielsen et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN 1190893 A 8/1998
CN 1867360 A 11/2006

(Continued)

OTHER PUBLICATIONS

Wang et al., "Non-peptidic glucose-like peptide-1 receptor agonists:
aftermath of a serendipitous discovery," Acta Pharmacol. Sinica
31:1026-1030 (2010) (Year: 2010).
Beglinger C et al., Clinical Pharmacology and
Therapeutics, "Pharmacokinetics and Pharmacodynamic Effects of
Oral GLP-1 and PYY3-36: A Proof-Of-Concept Study in Healthy
Subjects", 2008, vol. 84, No. 4, pp. 468-474.
Steinert RE et al, American Journal of Clinical Nutrition, "Oral
Administration of Glucagon-Like Peptide 1 or Peptide YY 3-36
Affects Food Intake in Healthy Male Subjects", 2010, vol. 92, pp.
810-817.

(Continued)

Primary Examiner — Julie Ha

Assistant Examiner — Kristina M Hellman

(74) Attorney, Agent, or Firm — Leon Y. Lum

(57) ABSTRACTThe present invention relates to solid compositions com-
prising a GLP-1 agonist and a salt of N-(8-(2-hydroxyben-
zoyl)amino)caprylic acid and their use in medicine.**9 Claims, No Drawings****Specification includes a Sequence Listing.**